SFEBES2018 Symposia Breast cancer (3 abstracts)
The Estrogen Receptor chromatin binding landscape in human tumors
Stacey Joosten 1, , Tesa Severson 1, , Yongsoo Kim 1, , Karianne Schuurman 1, , Paul van Diest 3 , Lodewyk Wessels 1, & Wilbert Zwart 1,
1Netherlands Cancer Institute, Amsterdam, Netherlands; 2Oncode Institute, Utrecht, Netherlands; 3UMC Utrecht, Utrecht, Netherlands.
Estrogen Receptor alpha (ER) is the key driver in the majority of all breast cancers, and considered the main target for therapy. However, resistance to treatment is common and biomarkers to facilitate optimal treatment selection are urgently needed. Even though the vast majority of breast cancer patients are female, breast cancer can develop in men as well. Using chromatin immunoprecipitation followed by massive-parallel sequencing (ChIP-seq), we identified the genome-wide chromatin binding profiles of ER in male and female breast tissue, which we compared with profiles found in cell lines. Interestingly, while in cell lines only ~5% of ER chromatin binding sites are observed at promoter regions, a substantially higher promoter-occupancy of ER was found in tumor tissue from both sexes. By assessing inter-tumor heterogeneity of ER chromatin binding sites, a stronger conservation of promoter-binding by ER was found as compared to enhancer regions, which was directly compared with enhancer activity analyses in healthy breast tissue. By integrating both ‘common’ and ‘unique’ ER-bound enhancers with somatic mutation data and breast cancer risk SNPs, we aim to identify whether diversity of enhancer action and ER genomic selectivity between tumors may represent a driving factor in tumor development and progression.
Volume 59
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more